Pharmaco-pharmaceutical investment promotion risk awareness will go steady

Pharmaceutical investment agents are also called “doing drug free people”. They continue to mature under the industry's rules of the game and continue to regulate. They create more profits for drug manufacturers, and also solve the operational risks of drug manufacturers. The cooperative relationship between pharmaceutical agents and pharmaceutical manufacturers has broken through the original model of regional cooperation. More agents and manufacturers are cooperative relations with provincial distributors and even national distributors. Agents not only cooperate with small and medium-sized manufacturing companies, but also cooperate with well-known large and medium-sized enterprises. Many well-known large and medium-sized companies have launched new products. The first consideration is to cooperate with powerful agents in the national distributors.

Many pharmaceutical investment enterprises have implemented a market-buying agency system on the basis of their original offices. The company has a simple management relationship with these agents, and will not be able to lose too much network resources, and share risk sharing. The interests of the cooperative relations, so that the company why not? Finding new pharmaceutical investment agents and consolidating old agents is an important part of the company's national drug fair, and companies can't ignore it.

The rise of the population of pharmaceutical investment agents and the continuous maturity of norms have broken the operating pattern of Chinese pharmaceutical manufacturers and changed the marketing concepts and marketing models of the manufacturers. Pharmaceutical manufacturers want to establish their own sales network to maximize profits. In the past few years, many companies have successively learned about the successful management and marketing concepts of foreign companies, established offices around the country, and detailed management. But learning was not successful, and some paid a heavy price. In the period of socio-economic transition, people's “honesty” has been tested, and companies are suffering from risks in the business process, and they are also exposed to the risks of “integrity”. The agent model then solves these business worries and eliminates excessive administrative expenses.

In the view of insiders of pharmaceutical investment enterprises, the pharmaceutical marketing industry in China has stepped into the “post-investment era.” In the “post-investment era”, what pharmaceutical companies should do, how to do it, and how to go more smoothly on the road to investment promotion, Has become a series of issues that cannot be avoided and must be considered calmly.

Experts in pharmaceutical investment agency believe that products are the key to the existence and operation of commercial enterprises, and they are also the fundamental factors that restrict their development. Therefore, the orientation of product agents needs careful consideration. Under the current industry environment, commercial enterprises cannot impulsively represent a good variety, so as to avoid spending a lot of manpower, material resources and energy, and still fail to do so. Pharmaceutical investment enterprises should combine their own advantages in resources, agents and the company's positioning to match the direction of the product, will be able to contribute.

For pharmaceutical investment promotion companies, in most markets, the main partners are individuals who have rich local resources and personal connections. Pharmaceutical investment promotion companies have developed to the current resident investment promotion phase and have already had a fairly good say in the local resources and market conditions. When individual agents and businesses cannot effectively develop, it is also necessary to rely on the company’s own team to develop terminals. A good way. The pharmaceutical agents, as the root of the survival of the investment enterprises, need to work hard to establish a more understanding relationship with each other. Only in this way can the development of the company be guaranteed. Therefore, when dealing with pharmaceutical agents, pharmaceutical investment merchants must also proceed from the actual needs of the agents and become passive in their initiative. They will firmly lock the pharmaceutical investment agents around the company.

Investing in what scope depends on the fact that pharmaceutical investment promotion companies need to clearly understand their internal resources when investing, rather than empty-hearted. Everyone wants to expand their sales area. It is best to recruit businesses to recruit Taiwan. In the understanding of pharmaceutical investment advertisements, many pharmaceutical investment companies do not have regional restrictions. Such a large-scale dissemination of nets generally brings such consequences: that is, some areas have more transactions, some areas have fewer transactions, and a large number of “chicken ribs” are formed. "Markets" are not worth investing in, not investing in and being very available, and the final result is often that they do not invest in market support, causing the market to die a lot, and once the market is ruined, it will have to pay an extremely high price if it wants to weigh heavily.